Nañez A, Stram DA, Garcia C, et al. - In a pragmatic clinical setting with > 1 year follow up , CA 125 and transvaginal ultrasound surveillance were assessed in women with BRCA1 or BRCA2 pathogenic variants. Researchers conducted a retrospective cohort study including 1,418 women (aged ≥ 30 years) with a BRCA1 or BRCA2 pathogenic variant with at least one intact ovary. Annual ovarian cancer surveillance with ultrasound and CA 125 beyond 1 year was reported in only 20% of BRCA carriers with ovaries. Yearly decline in adherence to annual surveillance with CA 125 and ultrasound was observed from time of gene test. With 2,731 surveillance CA 125 and ultrasound tests detection of only two ovarian cancers was made. These findings question the utility of CA 125 and ultrasound surveillance for ovarian cancer detection in women with BRCA1 or BRCA2 pathogenic variants.